We present a case report of severe gastritis and colitis in the context of recent zolbetuximab administration in a patient receiving combination chemotherapy for metastatic gastric adenocarcinoma. This case highlights the potential gastrointestinal toxicity associated with zolbetuximab, particularly in patients with previous mucosal injury from chemotherapy and tumor involvement.